

## DAFTAR PUSTAKA

1. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. 2021;26(10):1–101.
2. Leo S De, Lee SY, Braverman LE, Unit E, Sciences C. Hyperthyroidism\_Lancet review. Lancet. 2016;388(10047):906–18.
3. Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018;14(5):301–16.
4. Doubleday AR, Sippel RS. Hyperthyroidism. Gland Surg. 2020;9(1):124–35.
5. Sippel, Rebecca S. Chen H. The Handbook Of Endocrine Surgery. New York: World Scientific Publishing Co. Pte. Ltd; 2012.
6. Marinò M, Latrofa F, Menconi F, Chiovato L, Vitti P. Role of genetic and non-genetic factors in the etiology of Graves' disease. J Endocrinol Invest. 2015;38(3):283–94.
7. Harris T, Creed F, Brugha TS. Stressful life events and Graves' disease. Br J Psychiatry. 1992;161(OCT.):535–41.
8. Wiersinga WM. Smoking and thyroid. Clin Endocrinol (Oxf). 2013;79(2):145–51.
9. Vija Racaru L, Fontan C, Bauriaud-Mallet M, Brillouet S, Caselles O, Zerdoud S, et al. Clinical outcomes 1 year after empiric 131I therapy for hyperthyroid disorders: Real life experience and predictive factors of functional response. Nucl Med Commun. 2017;38(9):756–63.
10. Wong KK, Shulkin BL, Gross MD, Avram AM. Efficacy of radioactive iodine treatment of graves' hyperthyroidism using a single calculated 131I dose. Clin Diabetes Endocrinol. 2018;4(1):1–8.
11. Silberstein EB, Alavi A, Balon HR, Clarke SEM, Divgi C, Gelfand MJ, et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med. 2012;53(10):1633–51.
12. Namwongprom S, Unachak K, Dejkharnon P, Ua-apisitwong S,

- Ekmahachai M. Radioactive iodine for thyrotoxicosis in childhood and adolescence: Treatment and outcomes. *JCRPE J Clin Res Pediatr Endocrinol*. 2013;5(2):95–7.
13. Fanning E, Inder WJ, Mackenzie E. Radioiodine treatment for graves' disease: A 10-year Australian cohort study. *BMC Endocr Disord*. 2018;18(1):1–6.
  14. Moon JH, Yi KH. The Diagnosis and Management of Hyperthyroidism in Korea: Consensus Report of the Korean Thyroid Association. *Endocrinol Metab*. 2013;28(4):275.
  15. Glinoeer D. The diagnosis and treatment of Graves' disease in Europe. Differences and similarities with Japan and the United States. *Eur J Intern Med Suppl*. 1992;3(1):84–90.
  16. Thewjitcharoen Y, Karndumri K, Chatchomchuan W, Porramatikul S, Krittiyawong S, Wanathayanoroj E, et al. Practice patterns and outcomes in the management of Thai patients with Graves' disease. *Thyroid Res*. 2021;14(1):1–8.
  17. Beshyah SA, Khalil AB, Sherif IH, Benbarka MM, Raza SA, Hussein W, Alzahrani AS. A Survey Of Clinical Practice Patterns In Management of Graves Disease in The Middle East and North Africa. *Endocr Pr*. 2017;299–308.
  18. Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of graves' disease. *J Clin Endocrinol Metab*. 2012;97(12):4549–58.
  19. Bakos B, Takács I, Nagy Z, Kósa JP, Balla B, Tóbiás B, et al. Long term efficacy of radioiodine treatment in hyperthyroidism. *Exp Clin Endocrinol Diabetes*. 2013;121(8):494–7.
  20. Kuanrakcharoen P. Radioiodine (I-131) dose for the treatment of hyperthyroidism in Rajavithi hospital. *J Med Assoc Thail*. 2016;99:S123–9.
  21. Schiavo M, Bagnara MC, Pomposelli E, Altrinetti V, Calamia I, Camerieri L, Giusti M, Pesce G, Reitano C, Bagnasco M CM. Radioiodine therapy of hyperfunctioning thyroid nodules: usefulness of an implemented dose calculation algorithm allowing reduction of radioiodine amount. *Q J Nucl*

- Med Mol Imaging. 2013;57(3):301–7.
22. Santos RB, Romaldini JH, Ward LS. A randomized controlled trial to evaluate the effectiveness of 2 regimens of fixed iodine ( $^{131}\text{I}$ ) doses for graves disease treatment. *Clin Nucl Med*. 2012;37(3):241–4.
  23. Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, et al. The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. *Eur Thyroid J*. 2016;5(1):9–26.
  24. Thientunyakit T, Thongmak S, Premprapha T. Comparative evaluation of two different dosage calculation protocols of iodine-131 in the treatment of hyperthyroidism. *J Med Assoc Thai*. 2010;93(8):969–77.
  25. Fong LY, Shuaib IL, Hamzah F. The outcome of a calculated radioiodine dose based on pertechnetate thyroid uptake ratio in treatment for hyperthyroidism. *Malaysian J Med Heal Sci*. 2018;14:71–5.
  26. Kuanrakcharoen P. Success Rates and their Related Factors in Patients Receiving Radioiodine ( $\text{I-131}$ ) Treatment for Hyperthyroidism. *J Med Assoc Thai*. 2017;100(Suppl 1):183–91.
  27. Knapska-Kucharska M, Oszukowska L, Lewiński A. Analysis of demographic and clinical factors affecting the outcome of radioiodine therapy in patients with hyperthyroidism. *Arch Med Sci*. 2010;6(4):611–6.
  28. Finessi M, Bisceglia A, Passera R, Rossetto Giaccherino R, Pagano L, Castellano G, et al. Predictive factors of a worse response to radioactive Iodine- $\text{I131}$  treatment in hyperthyroidism: outcome analysis in 424 patients. A single centre experience. *Endocrine*. 2021;73(1):107–15. <http://dx.doi.org/10.1007/s12020-020-02573-1>, diakses pada 24 September 2021 pukul 21.45 WIB.
  29. Körber C, Schneider P, Körber-Hafner N, Hänscheid H, Reiners C. Antithyroid drugs as a factor influencing the outcome of radioiodine therapy in Graves' disease and toxic nodular goitre? *Eur J Nucl Med*. 2001;28(9):1360–4.
  30. Bonnema SJ, Hegedüs L. Radioiodine therapy in benign thyroid diseases: Effects, side effects, and factors affecting therapeutic outcome. *Endocr*

Rev. 2012;33(6):920–80.

31. LiVolsi VA, Baloch ZW. The Pathology of Hyperthyroidism. *Front Endocrinol (Lausanne)*. 2018;9(December).
32. Di Martino F, Traino AC, Brill AB, Stabin MG, Lazzeri M. A theoretical model for prescription of the patient-specific therapeutic activity for radioiodine therapy of graves' disease. *Phys Med Biol*. 2002;47(9):1493–9.
33. Abd-ElGawad M, Abdelmonem M, Ahmed AE, Mohammed OM, Zaazouee MS, Assar A, et al. Lithium carbonate as add-on therapy to radioiodine in the treatment on hyperthyroidism: a systematic review and meta-analysis. *BMC Endocr Disord*. 2021;21(1):1–11.
34. Pusuwan P, Tuntawiroon M, Sritongkul N, Chaudakshetrin P, Nopmaneejumruslers C, Komoltri C, et al. A prospective randomized study of the efficacy and cost-effectiveness of high and low dose regimens of I-131 treatment in hyperthyroidism. *J Med Assoc Thail*. 2011;94(3):361–8.
35. Metso S, Jaatinen P, Huhtala H, Luukkaala T, Oksala H, Salmi J. Long-term follow-up study of radioiodine treatment of hyperthyroidism. *Clin Endocrinol (Oxf)*. 2004;61(5):641–8.
36. Pena Pardo FJ, López Serrano R, García Cases FJ, Redal Peña MC, Crespo-Jara A, García Vicente AM, et al. A prospective comparative study of two methods for the individual calculation of 131I activity in the treatment of hyperthyroidism. *Endocrinol Diabetes y Nutr (English ed)*. 2020;67(9):568–77.
37. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated 131 iodine activity. Results from a prospective, randomized, multicentre study. *Eur J Clin Invest*. 1995;25(3):186–93.
38. Amato E, Campennì A, Leotta S, Ruggeri RM, Baldari S. Treatment of hyperthyroidism with radioiodine targeted activity: A comparison between two dosimetric methods. *Phys Medica*. 2016;32(6):847–53. <http://dx.doi.org/10.1016/j.ejmp.2016.05.059>, diakses pada 24 September 2021 pukul 20.49 WIB.
39. Lewis A, Rea T, Atkinson B, Bell P, Courtney H, Mccance D, et al.

- Outcome of <sup>131</sup>I therapy in hyperthyroidism using a 550MBq fixed dose regimen. 2013;82(2):85–8.
40. Omotayo Ogunjobi K, Enyi Ejeh J, Solomon Adedapo K, Eniojukan JF. Effectiveness of Fixed Dose Radioactive Iodine (RAI) for the Treatment of Hyperthyroidism: Experience of a Teaching Hospital in South West Nigeria. *Molecular Imaging Radionucl Ther.* 2013;22(2):36–41.
  41. Sapienza MT, Coura-Filho GB, Willegaignon J, Watanabe T, Duarte PS, Buchpiguel CA. Clinical and dosimetric variables related to outcome after treatment of graves' disease with 550 and 1110 MBq of <sup>131</sup>I: Results of a prospective randomized trial. *Clin Nucl Med.* 2015;40(9):715–9.
  42. Gigliotti BJ. Fixed-Dose Radioactive Iodine Reduces Goiter Size and Alleviates Hyperthyroidism in Most Patients with Toxic Multinodular Goiter. *Clin Thyroidol.* 2020;32(6):273–5.
  43. Salih A. Thyroglobulin as a possible predictor of doses radioiodine therapy in hyperthyroidism. *Acta Medica Salin.* 2018;48(1–2):12–5.
  44. Chen DY, Schneider PF, Zhang XS, He ZM, Jing J, Chen TH. Striving for euthyroidism in radioiodine therapy of graves' disease: A 12-year prospective, randomized, open-label blinded end point study. *Thyroid.* 2011;21(6):647–54.
  45. Täeb D, Bournaud C, Eberle MC, Catargi B, Schwartz C, Éatrice Cavarec MB, et al. Quality of life, clinical outcomes and safety of early prophylactic levothyroxine administration in patients with Graves' hyperthyroidism undergoing radioiodine therapy: A randomized controlled study. *Eur J Endocrinol.* 2016;174(4):491–502.
  46. Dora JM, Escouto Machado W, Andrade VA, Scheffel RS, Maia AL. Increasing the radioiodine dose does not improve cure rates in severe graves' hyperthyroidism: A clinical trial with historical control. *J Thyroid Res.* 2013;2013.
  47. Schneider DF, Sonderman PE, Jones MF, Ojomo KA, Chen H, Jaume JC, et al. Failure of Radioactive Iodine in the Treatment of Hyperthyroidism. *Ann Surg Oncol.* 2014;21(13):4174–80.
  48. Szumowski P, Abdelrazek S, Kociura Sawicka A, Mojsak M, KostECKi J,

- Sykała M, et al. Radioiodine therapy for Graves' disease — retrospective analysis of efficacy factors. *Endokrynol Pol.* 2015;66(2):126–31.
49. Khalid Y, Barton DM, Baskar V, Jones HKP, West TET, Buch HB. Efficacy of fixed high dose radioiodine therapy for hyperthyroidism - a 14 year experience: A focus on influence of pre-treatment factors on outcomes. *Br J Med Pract.* 2011;4(3):3–6.
50. Tabuenca-Dopico O, Boente-Varela R, Lamas-Ferreiro JL. Study of factors that influence the outcome of 131 I treatment in hyperthyroidism secondary to nodular goitre. *Rev Española Med Nucl e Imagen Mol English Ed.* 2017;36(6):356–61. <http://dx.doi.org/10.1016/j.remnie.2017.09.003>, diakses pada 22 Oktober 2021 pukul 13.53 WIB.
51. Mijnhout GS, Franken AAM. Antithyroid drug regimens before and after 131I-therapy for hyperthyroidism: Evidence-based? *Neth J Med.* 2008;66(6):238–41.
52. Zakavi SR, Khazaei G, Sadeghi R, Ayati N, Davachi B, Bonakdaran S, et al. Methimazole discontinuation before radioiodine therapy in patients with Graves disease. *Nucl Med Commun.* 2015;36(12):1202–7.
53. Andrade VA, Gross JL, Maia AL. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: One-year follow-up of a prospective, randomized study. *J Clin Endocrinol Metab.* 2001;86(8):3488–93.
54. Walter MA, Briel M, Christ-Crain M, Bonnema SJ, Connell J, Cooper DS, et al. Effects of antithyroid drugs on radioiodine treatment: Systematic review and meta-analysis of randomised controlled trials. *Br Med J.* 2007;334(7592):514–7.
55. Kyrilli A, Tang BNT, Huyge V, Blocklet D, Goldman S, Corvilain B, et al. Thiamazole pretreatment lowers the 131I activity needed to cure hyperthyroidism in patients with nodular goiter. *J Clin Endocrinol Metab.* 2015;100(6):2261–7.
56. Ma C, Xie J, Wang H, Li J, Chen S. Radioiodine therapy versus antithyroid medications for Graves' disease. *Cochrane Database Syst Rev.* 2016;2016(2).

57. Ahmed FW, Kirresh OZ, Majeed MS, Iftikhar M, Sajid MS. Meta-Analysis of Randomized Controlled Trials Comparing the Efficacy of Radioactive Iodine Monotherapy versus Radioactive Iodine Therapy and Adjunctive Lithium for the Treatment of Hyperthyroidism. *Endocr Res* . 2021;46(4):160–9. <https://doi.org/10.1080/07435800.2021.1924769>, diakses pada 24 September 2021 pukul 21.44 WIB.
58. Kessler L, Palla J, Baru JS, Onyenwenyi C, George AM, Lucas BP. Lithium as an adjunct to radioactive iodine for the treatment of hyperthyroidism: A systematic review and meta-analysis. *Endocr Pract*. 2014;20(7):737–45.
59. Lazarus JH. Lithium and thyroid. *Best Pract Res Clin Endocrinol Metab*. 2009;23(6):723–33. <http://dx.doi.org/10.1016/j.beem.2009.06.002>, diakses pada 21 September 2021 pukul 15.34 WIB.
60. Genovese BM, Noureldine SI, Gleeson EM, Tufano RP, Kandil E. What is the best definitive treatment for graves' disease? A systematic review of the existing literature. *Ann Surg Oncol*. 2013;20(2):660–7.
61. Törring O, Watt T, Sjölin G, Byström K, Abraham-Nordling M, Calissendorff J, et al. Impaired Quality of Life after Radioiodine Therapy Compared to Antithyroid Drugs or Surgical Treatment for Graves' Hyperthyroidism: A Long-Term Follow-Up with the Thyroid-Related Patient-Reported Outcome Questionnaire and 36-Item Short Form Health Status . *Thyroid*. 2019;29(3):322–31.

